Paradigm Announces Major Improvement Enabling Comprehensive Next Generation Sequencing Including Mutational Load Off of a Single Slide in Five Business Days
PHOENIX, Sept. 26, 2018 /PRNewswire/ -- Paradigm today announced the commercial release of a substantially improved next generation sequencing (NGS) panel for patients with late stage and aggressive cancer. The Paradigm Cancer Diagnostic (PCDx) has been upgraded to now offer oncologists the ability to obtain full actionable NGS results including mutational load from a single microscope slide with the same industry leading turnaround time of five business days or less. In addition to the slide for NGS, a corresponding slide is required for the H&E as well as for each of the typically eight immunohistochemistry (IHC) panel that may be performed including PDL-1 and MMR.
"While tumor blocks are preferable, they simply aren't always available. From the clinic's perspective, ordering a full NGS panel using PCDx can now be no different from ordering a routine IHC or diagnostic stain," said Scott Morris, PhD, Chief Scientific Officer. "With the emergence of immune checkpoint inhibitors and the growing importance of mutational load that often requires a substantial amount of tumor, we offer a solution for the most patients, including the one in five who would not get results from other providers that require more specimen and the even larger amount of clients who need actionable results more quickly."
PCDx is offered in a College of American Pathologists (CAP) accredited laboratory and is covered by most insurance plans including Medicare.
The Paradigm Cancer Diagnostic (PCDx) is a clinical-grade comprehensive sequencing test that interrogates DNA, mutational load, RNA and fusions as well as protein by immunohistochemistry and delivers a report in five business days. The PCDx report applies evidence curated by our team of oncologists and scientists linking up to 90 different FDA approved therapies and 24 combinations as well as the latest clinical trials to help guide the treatment decisions. In an independent prospective study, using PCDx to help guide treatment decisions has been clinically proven to significantly increase progression free survival.
For more information visit www.paradigmdx.com.